Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement,
and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS)
or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs)
treatment. Responding patients are eligible to continue treatment until loss of
response/disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
GCP-Service International West GmbH
Collaborators:
Australasian Leukaemia and Lymphoma Group German Myelodysplastic Syndrome Study Group Geron Corporation Groupe Francophone des Myelodysplasies QIMR Berghofer Medical Research Institute Saint-Louis Hospital, Paris, France Universitätsklinikum Leipzig